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Abstract
Introduction In highly emetogenic chemotherapy, the rec-
ommended dose of the serotonin-receptor antagonist
ondansetron (5 mg/m2 q8h) may be insufficient to prevent
chemotherapy-induced nausea and vomiting. In adults,
ondansetron-loading doses (OLD) of 32 mg are safe. We
aimed to evaluate in children the safety of an OLD of
16 mg/m2 (top, 24 mg) i.v., followed by two doses of
5 mg/m2 q8h.
Materials and methods This retrospective single-center
study included all pediatric oncology patients having
received ≥1 OLD between 2002 and 2005. Adverse events
(AE) definitely, probably, or possibly related to OLD were
studied, excluding AE not or unlikely related to the OLD.
Associations between potential predictors and at least
moderate AE were analyzed by mixed logistic regression.
Results Of 167 patients treated with chemotherapy, 37 (22%)
received 543 OLD. The most common AE were hypotension,
fatigue, injection site reaction, headache, hot flashes/flushes,
and dizziness. At least mild AE were described in 139 OLD
(26%), at least moderate AE in 23 (4.2%), and severe AE in 5
(0.9%; exact 95% confidence interval [CI], 0.4–2.1). Life-
threatening or lethal AE were not observed (0.0%; 0.0–0.6).
At least moderate AE were significantly more frequent in
female patients (odds ratio [OR] 3.5; 95% CI 1.4–8.8; p=
0.010), after erroneously given second OLD (17.0; 1.9–154;
p=0.012) and higher 24 h cumulative surface corrected
dose (1.26 per mg/m2; 1.06–1.51; p=0.009). OLD given
to infants below 2 years were not associated with more
frequent AE.
Conclusions Ondansetron-loading doses of 16 mg/m2
(top, 24 mg) i.v. seem to be safe in infants, children, and
adolescents.
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Introduction
Nausea and vomiting remain one of the three most distress-
ing side effects of chemotherapy [8]. Specific serotonin
(5-HT) receptor antagonists are generally accepted as the
standard of care for prophylaxis of emesis [9, 12]. In highly
emetogenic chemotherapy, the recommended doses are
often insufficient, however. Optimal pediatric dosing and
scheduling of antiemetics remain uncertain, and large ro-
bust trials are needed [1]. Due to variation of pharmaco-
kinetic parameters in children, higher weight-based doses
of 5-HT3 antagonists than those used in adults may be
required for antiemetic protection [12]. The question is
whether higher doses are also safe.
The standard dose of ondansetron, a selective 5-HT3
receptor antagonist, is 5 mg/m2 (top dose, 8 mg) given
intravenously or orally every 8 h. In adults, ondansetron
loading doses (OLD) of 32 mg applied intravenously have
been shown to be safe and well tolerated [19], while com-
parable data in children are rare. One prospective, random-
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ized, double-blind study found no clinical or laboratory
toxicity after application of 16 ondansetron doses of
0.6 mg/kg in children, corresponding to about 18 mg/m2,
top dose 32 mg [18].
The aim of this retrospective single center study was to
determine whether an OLD of 16 mg/m2 (top dose, 24 mg),
administered intravenously before chemotherapy and fol-
lowed by doses of 5 mg/m2 (top dose, 8 mg) every 8 h, was
safe in children and adolescents.
Materials and methods
Patients
Since 2002, all patients diagnosed with a malignancy
treated with severely emetogenic chemotherapy at the
Division of Pediatric Hematology/Oncology, Department
of Pediatrics, University of Bern, Switzerland routinely
received OLD. Patients receiving moderately emetogenic
chemotherapy in whom nausea and emesis was not
controlled by the standard dose of ondansetron, i.e., 5 mg/m2
(top, 8 mg) given orally or intravenously every 8 h, received
OLD as well.
Eligible for this retrospective single-center study were all
patients up to the age of 17 years, who had received at least
one OLD between January 1, 2002 and December 31, 2005.
This study had been approved by the institutional review
board.
Definitions
The OLD was given intravenously, 16 mg/m2 (top dose,
24 mg) over 15 min, half an hour before starting chemo-
therapy. It was followed by two intravenous or oral doses of
ondansetron (5 mg/m2; top dose, 8 mg) every 8 h. Data on
adverse events (AE) was collected for 24 h after adminis-
tration of the OLD.
The Common Terminology Criteria for Adverse Events
(CTCAE; Version 3.0) were used to specify and quantify
AE [23]. Severity of AE was divided into five grades: mild,
moderate, severe, life-threatening, and death due to AE.
Furthermore, it was described whether AE were definitely,
probably, possibly, unlikely, or not related to the OLD [14].
Chemotherapy was classified into four levels of emeto-
genic risk, i.e., minimal (emesis in <10%) like vincristine,
low (10 to 30%) like etoposide, moderate (30 to 90%) like
ifosfamide, and high (>90%) like cisplatin [12].
Data assessment
Patient characteristics (sex, age at diagnosis, diagnosis, and
relapse status), emetogenic risk of chemotherapy, and infor-
mation on AE including quality, severity, and relation to
OLD were extracted retrospectively from patient records.
Statistical analysis
Because of non-normally distributed data, median, interquar-
tile range (IQR), and range were calculated. Exact Blyth–
Still–Casella 95% confidence intervals (CI) were calculated
for proportions. The exact Fisher–Freeman Halton test was
used for comparing proportions, and mixed logistic regres-
sion (penalized quasi-likelihood method) for comparison of
AE risks between different groups. Two-sided tests were
applied throughout, and p values below 0.05 were consid-
ered significant. The softwares used were StatXact 6 (Cytel
Software, Cambridge, MA, USA) and R 2.4.0 (R Foundation
for Statistical Computing, Vienna, Austria).
Results
Patients
In the 4 years studied, 167 patients were diagnosed with
cancer requiring chemotherapy, with 37 (22%) of them
receiving at least one OLD. The proportion of children
receiving OLD was significantly lower in those with leuke-
mia or lymphoma vs those with solid tumor within or
outside the central nervous system, while there were no
differences as to age at diagnosis, gender, and relapse status
(Table 1). The median age of the 37 children studied here
was 6.9 years when receiving their first OLD (range, 0.4 to
15.7). The smallest child weighed 4.4 kg, with a calculated
body surface area of 0.26 m2.
Ondansetron-loading doses
During the study period, these 37 patients received 543
OLD (median per patient, 12; range, 1 to 46) during 231
cycles of chemotherapy. As intended, 508 (94%) OLD were
administered intravenously, while 35 (6%) were given orally.
Only four (0.7%) OLD were given as antiemetic therapy,
while the remaining 539 (99.3%) doses were applied pro-
phylactically. As additional antiemetic medication, dexa-
methasone (2 mg/m2 q8h) was given in 454 (84%) of the
OLD, dexamethasone together with lorazepam in 12 (2.2%),
and lorazepam in 1 (0.2%), while the OLD was administered
without concurrent antiemetic medication 76 (14%) times.
The median OLD was 16 mg (IQR, 12 to 24; range, 4 to
25). The intended top dose of 24 mg, corresponding to a
body surface area of at least 1.5 m2, was given 175 times
(32%), while it was exceeded once (0.2%; 25 mg). The
median surface-corrected dose was 15.6 mg/m2 (IQR, 14.8
to 16.2; range, 10.7 to 20.5). The OLD was dosed as in-
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tended, i.e., 16 mg/m2±15% (13.6 to 18.4 mg/m2), with a
top dose of 24 mg, 503 (93%) times, while doses were too
low 10 (1.8%) times and too high 30 (5.5%) times (Fig. 1).
Of the 543 OLD, 528 (97%) were followed as intended
by two conventional ondansetron doses every 8 h, while 9
(1.7%) times only one conventional dose, and 6 (1.1%) times
no further ondansetron dose was administered. After three
(0.6%) OLD, a second OLD was administered erroneously
within 3.5 to 6.5 h. The median cumulative ondansetron dose
over 24 h was 31 mg. The median cumulative surface cor-
rected dose, aiming at 26 mg/m2, was 26.1 mg/m2 (IQR, 24.7
to 27.8; range, 13.5 to 36.1).
Observed adverse events
In total, 356 AE were reported. There were 298 mild AE,
45 moderate AE, and 13 severe AE, while there were no
life-threatening or lethal AE. As 190 AE were considered
not or unlikely to be related to the OLD, only the remaining
166 AE at least possibly related were further studied. Of
these, 140 (84%) AE were mild, 21 (13%) moderate, and 5
(3.0%) severe. The most common AE were hypotension
and fatigue (31 each), injection site reaction (16), headache
(15), hot flashes/flushes (14), and dizziness (11; Table 2).
In 139 OLD (25.6%; exact 95% CI 22.0 to 29.4), at least
one AE at least possibly related to the OLD was observed.
In 23 (4.2%; 2.8 to 6.3) of these OLD, an AE was at least
moderate, and in 5 (0.9%; 0.4 to 2.1) of these OLD, the AE
was severe. See Table 3 for details and for the respective
numbers when the three OLD that were followed errone-
ously by a second OLD were excluded from analysis.
Of interest, OLD given to infants below 2 years were not
associated with more AE than in older children: In infants,
at least one mild AE at least possibly related to the OLD
was recorded in 6 of 52 OLD (12%; 5 to 23), while there
were no moderate or severe AE recorded in OLD in these
infants.
The severe AE reported to be at least possibly related to
five OLD included dizziness, headache, and abdominal pain.
There were two patients experiencing severe AE probably or
definitely related to anOLD: First, a girl aged 16 years, treated
for medulloblastoma, developed severe dizziness plus mod-
erate injection site reaction immediately after receiving
erroneously a second OLD after 3.5 h, leading to a cumulative
Fig. 1 Ondansetron-loading doses given to patients with a body
surface area of 1.5 m2 at most (total, 375). Children with a higher
surface area received the top dose of 24 mg
Table 1 Patient characteristics
OLD indicates ondansetron
loading dose
p p value resulting from exact
Fisher–Freeman–Halton tests;
CNS central nervous system
*Of the 12 patients treated for
both initial diagnosis and re-
lapse during the study period,
one received at least one OLD
Characteristic All patients Patients receiving at least one OLD
Number Number
(proportion)
OLD per patient:
median (range)
OLD in total
(proportion)
Total 167 37 (22%) 12 (1 to 46) 543 (100%)
Diagnosis ( p<0.001)
Leukemia 77 5 (6%) 2 (1 to 18) 26 (5%)
Lymphoma 24 2 (8%) 11 (5 to 16) 21 (4%)
CNS tumor 25 13 (52%) 11 (4 to 18) 133 (24%)
Solid tumor outside CNS 41 17 (41%) 18 (4 to 46) 363 (67%)
Age at diagnosis ( p=0.63)
<2 years 33 6 (18%) 9 (4 to 14) 52 (10%)
≥2 and <6 years 47 11 (23%) 13 (4 to 46) 173 (32%)
≥6 and <12 years 49 9 (18%) 8 (1 to 36) 103 (19%)
≥12 years 38 11 (29%) 18 (1 to 44) 215 (40%)
Gender ( p=0.85)
Female 81 17 (21%) 9 (1 to 46) 220 (41%)
Male 86 20 (23%) 14 (1 to 44) 323 (59%)
Relapse status* ( p=1.00)
Initial diagnosis 159 34 (21%) 12 (1 to 44) 479 (88%)
Relapse 20 4 (20%) 17 (8 to 22) 64 (12%)
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ondansetron dose of 28 mg/m2. Second, a 5-year-old girl
treated for osteosarcoma developed severe abdominal pain
2 h after receiving a correctly dosed OLD.
Factors associated with the risk of adverse events
Table 4 displays that double OLD, a higher 24 h cumulative
surface corrected dose, and female gender all were signifi-
cantly associated with an increased frequency of moderate or
severe AE. This was the case as well for a higher surface-
corrected loading dose and age above 2 years for mild,
moderate, or severe AE. The other factors examined were
not significantly associated with AE.
Antiemetic efficacy
Although the efficacy was not a primary endpoint, data on
frequency of emesis and nausea were collected in the chart
review. Complete or major control of emesis, i.e., not exceed-
ing one episode in 24 h, was achieved in 472 (87%) OLD.
In 393 (72%) OLD, no nausea or emesis at all was noted
in the charts.
Discussion
The results of this study indicate that OLD applied as
described to prevent or treat chemotherapy induced nausea
and vomiting in infants, children, and adolescents seem to be
safe and well tolerated. In 404 of 543 (74%) loading doses,
no adverse events at least possibly related to ondansetron
were reported. Side effects were usually mild in nature (116
OLD, 23%), while moderate (18, 3.3%) and severe (5, 0.9%)
adverse events occurred in few OLD only.
The most commonly reported adverse events at least
possibly related to the OLD in our study were fatigue and
Table 2 Adverse events
Indicated are the number of
adverse events reported, and
the respective proportion of
OLD in parentheses
Type of AE Grade of Adverse Events
Mild Moderate Severe Total
Hypotension 31 (5.7%) 0 0 31 (5.7%)
Fatigue 30 (5.5%) 1 (0.2%) 0 31 (5.7%)
Injection site reaction 12 (2.2%) 4 (0.7%) 0 16 (2.9%)
Pain–head/headache 8 (1.5%) 5 (0.9%) 2 (0.4%) 15 (2.8%)
Hot flashes/flushes 12 (2.2%) 2 (0.4%) 0 14 (2.6%)
Dizziness 9 (1.7%) 0 2 (0.4%) 11 (2.0%)
Pain–abdomen 8 (1.5%) 0 1 (0.2%) 9 (1.7%)
Constipation 7 (1.3%) 2 (0.4%) 0 9 (1.7%)
Allergic reaction 7 (1.3%) 1 (0.2%) 0 8 (1.5%)
Pain–extremity-limb 6 (1.1%) 1 (0.2%) 0 7 (1.3%)
Mood alteration–agitation 1 (0.2%) 2 (0.4%) 0 3 (0.6%)
Ocular–other (impaired vision) 1 (0.2%) 2 (0.4%) 0 3 (0.6%)
Pruritus 2 (0.4%) 0 0 2 (0.4%)
Edema: head and neck 2 (0.4%) 0 0 2 (0.4%)
Diarrhea 2 (0.4%) 0 0 2 (0.4%)
Dysphagia 0 1 (0.2%) 0 1 (0.2%)
Table 3 Adverse events at
least possibly related to
ondansetron-loading doses
AE Adverse event; OLD
ondansetron-loading dose
*After three (0.6%) OLD,
a second OLD had been
erroneously administered
within 8 h
Type of AE Number of OLD with at least 1 AE of the specified type (proportion;
exact 95% confidence interval)
540 single OLD as intended* All 543 OLD
At least mild AE 138 (25.6%; 21.9 to 29.4) 139 (25.6%; 22.0 to 29.4)
At least probably related to OLD 39 (7.2%; 5.2 to 9.7) 40 (7.4%; 5.3 to 9.9)
At least moderate AE 22 (4.1%; 2.6 to 6.0) 23 (4.2%; 2.8 to 6.3)
At least probably related to OLD 4 (0.7%; 0.3 to 1.8) 5 (0.9%; 0.4 to 2.1)
At least severe AE 4 (0.7%; 0.3 to 1.8) 5 (0.9%; 0.4 to 2.1)
At least probably related to OLD 1 (0.2%; 0.0 to 1.0) 2 (0.4%; 0.1 to 1.3)
At least life-threatening AE 0 (0.0%; 0.0 to 0.6) 0 (0.0%; 0.0 to 0.6)
Death as an AE 0 (0.0%; 0.0 to 0.6) 0 (0.0%; 0.0 to 0.6)
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hypotension (6% of OLD each), headache, injection site
reaction, hot flashes/flushes (3% each) and constipation,
abdominal pain, and dizziness (2% each). Both the incidence
and spectrum of adverse events reported were similar to those
of adults receiving an intravenous OLD of 32 mg [16, 17, 19]
and to those of children after a standard dose of 5 mg/m2
ondansetron, where headache was noted in 2 to 8%, consti-
pation in 1 to 3.5% and diarrhea in 2% besides rarer adverse
effects like dizziness, warm feeling, somnolence, rash, and
urticaria [5, 6, 13, 21].
Among the reports on OLD in pediatric patients, this is
the first study with safety as primary end point. In a pro-
spective, double-blind, randomized study, Sandoval et al.
[18] compared the antiemetic efficacy of a single high-dose
(0.6 mg/kg, corresponding to about 18 mg/m2, maximum
dose 32 mg) with a repeated standard dose (0.15 mg/kg,
maximum dose 8 mg, every 4 h) in 31 pediatric oncology
patients. The study suggested that single high-dose ondan-
setron was as efficacious as the multiple standard-dose
regimen and was well tolerated. No patient experienced any
clinical or laboratory toxicity (16 high doses of ondansetron
applied; toxicity in 0%; exact 95% CI, 0 to 20%). Brock
et al. [5] conducted a randomized, double-blind study,
comparing a standard dose of 5 to 10 mg/m2, i.e., a medium
dose of ondansetron, in 187 chemotherapy-naive children.
There was no difference in the control of emesis or nausea,
Table 4 Influence of characteristics of patients and of loading doses on the risk of at least moderate adverse events
Characteristic Loading doses OLD with at least moderate AE at least possibly related to OLD
Number Number (proportion)/*median
(interquartile range)
Odds ratio (95% CI) p value
Gender
Female 220 16 (7.3%) 3.54 (1.43–8.77) 0.010
Male 323 7 (2.2%) reference
Age at administration
<2 years 52 0 (0%) 0.00 (0.00-?) 1.00
≥2 and <6 y 155 10 (6.5%) 1.62 (0.56–4.67) 0.37
≥6 and <12 y 87 3 (3.4%) 0.73 (0.19–2.82) 0.65
≥12 years 249 10 (4.0%) reference
Diagnosis
Leukemia 26 2 (7.7%) 2.74 (0.53–14.2) 0.24
Lymphoma 21 2 (9.5%) 3.58 (0.66–19.5) 0.15
CNS 133 9 (6.8%) 2.55 (0.99–6.58) 0.062
Solid tumors 363 10 (2.8%) reference
Relapse status
Relapse 64 4 (6.3%) 1.33 (0.38–4.63) 0.66
No relapse 479 19 (4.0%) reference
Emetogenic risk of chemotherapy
Minimal (<10%) 2 0 (0%) 0.00 (0.00-?) 1.00
Low (10% to 30%) 20 2 (10%) reference
Moderate (30 to 90%) 316 12 (3.8%) 0.34 (0.08–1.39) 0.13
High (>90%) 205 9 (4.4%) 0.34 (0.08–1.46) 0.15
Loading dose (mg)* 16.0 (12.0–24.0) 16.0 (12.0–20.0) 1.00 (0.92–1.08) 0.91
Loading dose, surface-corrected (mg/m2)* 15.6 (14.8–16.2) 15.6 (14.8–16.4) 0.90 (0.65–1.25) 0.52
Cumulative dose (mg/24 h)* 31.0 (20.0–40.0) 26.0 (20.0–37.0) 1.03 (0.98–1.09) 0.22
Cumulative dose, surface-corrected (mg/m2/24 h)* 26.1 (24.7–27.8) 27.3 (25.5–28.6) 1.26 (1.06–1.51) 0.009
Application form of OLD
Intravenous 508 22 (4.3%) Reference
Oral 35 1 (2.9%) 0.70 (0.12–4.14) 0.69
Double loading dose
No 540 22 (4.1%) Reference
Yes 3 1 (33.3%) 17.0 (1.88–154) 0.012
Additional medication
Dexamethasone or Lorazepam 467 20 (4.3%) 1.15 (0.37–3.57) 0.81
None 76 3 (3.9%) Reference
*Indicates median (interquartile range) are indicated for continuously measured variables
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and both anti-emetic regimens were tolerated well. Four
adverse events (headache in two episodes, dizziness, and
warm feeling) were considered to be at least probably
related to the standard dose (5 mg/m2) compared to one
AE (headache) probably related to the medium dose of
10 mg/m2. In a randomized, double-blind, placebo-controlled
trial, Parker et al. [15] had applied 48 OLD of 0.45 mg/kg,
corresponding to about 14 mg/m2. No analysis of adverse
events was performed.
Surprisingly, girls appeared to suffer more AE than boys.
Although female patients are known to have a higher
incidence of chemotherapy-induced nausea and vomiting
than male patients [11, 19, 20], we do not know of any data
on gender-related differences of adverse effects of ondanse-
tron or of perceiving them.
Three times (0.6%) a second loading dose had errone-
ously been given. As expected, this led to a significantly
higher risk of at least moderate adverse events, as was a
higher surface-corrected cumulative dose. These results
show that OLD must not be arbitrarily increased. The top
dose in our patients had been set to 24 mg, clearly below
the OLD of 32 mg established in adult oncology. This top
dose had been exceeded only once (0.2%). Generally, the
adherence to dosing instructions was high with 93% of
doses lying within the accepted range of 16 mg/m2±15%.
A limitation of the present study is the retrospective
design, which can lead to missing data, especially on AE.
Both the physician and nurse’s chart records, however,
were searched through for AE to minimize this risk. The
fact that in infants no excess of AE was recorded might
reflect that either they are not more susceptible to side
effects of OLD or that an important part of the side effects
in this age group were recorded with a smaller probability
than in older children better able to communicate. As might
be anticipated when considering the severity of illness of
this patient population, it was sometimes difficult to
determine whether the adverse event was due to the
underlying malignancy itself, to chemotherapy, other
medication, or ondansetron. This problem, however, would
remain as well in a prospectively designed study. For
dexamethasone as a very frequent co-medication, potential-
ly linked to hot flashes, dizziness, mood alteration, and
edema, we did not find an increased frequency of AE.
An advantage of this study was the large sample size
with 543 OLD, which allowed to calculate 95% CI for AE
that are clearly smaller than those published before [5, 18].
Even for infants below 2 years, sample size was acceptable
with 52 OLD. Remarkably, few data about the use of
serotonin 5-HT3 receptor antagonists in infants have been
published [4]. One placebo-controlled study demonstrated
that standard ondansetron dose (0.1 mg/kg, corresponding
to 3 mg/m2) is well tolerated and effective in preventing
postoperative nausea and vomiting in patients younger than
2 years of age [10]. In our study, OLD given to infants were
not associated with more frequent AE described.
Chemotherapy-induced nausea and vomiting is still an
important problem both in adult [2, 3, 7, 22] and pediatric
oncology [9]. Besides approaches using new substances
like neurokinin antagonists [22] and new ways of applica-
tion like patient-controlled dosing of antiemetic drugs [9],
higher than standard doses of established substances, like
OLD, may help to reduce this problem.
In conclusion, we report that an ondansetron-loading
dose of 16 mg/m2 (maximum, 24 mg) i.v. to prevent
chemotherapy-induced nausea and vomiting in infants,
children, and adolescents with cancer seems to be safe
and well tolerated. In three quarters of OLD, no adverse
event possibly due to the OLD occurred at all. A severe AE
at least possibly related to the OLD occurred after five
doses (0.9%; exact 95% CI, 0.4 to 2.1%). However, an
upper dose limit exists, and OLD must not be increased
arbitrarily. Despite the fact that this is a retrospective study,
its results seem to be well-founded and clinically applica-
ble. However, they cannot directly be applied to other 5-HT
inhibitors.
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